Media Release

July 27, 2021

Ad hoc announcement pursuant to Art. 53 LR

Idorsia announces financial results for the first half 2021 - Building momentum towards becoming a fully-fledged biopharmaceutical company

Allschwil, Switzerland - July 27, 2021

Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2021.

Business highlights

  • Daridorexant for the treatment of insomnia under review with US FDA, EMA, and Swissmedic
  • Nine scientific presentations for daridorexant shared at SLEEP 2021
  • Ponesimod to treat relapsing forms of multiple sclerosis was approved by the US FDA and the European Commission, Idorsia receives first income from the revenue-sharing agreement in respect to ponesimod
  • Clazosentan NDA for the treatment of cerebral vasospasm post aneurysmal subarachnoid hemorrhage (aSAH) submitted to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in March 2021
  • "SOS-AMI"Phase 3 registration study with selatogrel in suspected acute myocardial infarction (AMI) initiated in June 2021
  • Phase 2 study with ACT-539313 for binge eating disorder initiated in March 2021
  • Results for MODIFY Phase 3 study with lucerastat for Fabry disease expected in Q4 2021
  • Results for PRECISION Phase 3 study with aprocitentan for resistant hypertension expected mid-2022
  • Results for CARE Phase 2b study with cenerimod for systemic lupus erythematosus expected in Q4 2021

Financial highlights

  • US GAAP operating expenses HY 2021 at CHF 265 million
  • Non-GAAPoperating expenses HY 2021 at CHF 248 million
  • Guidance for 2021: US GAAP operating expenses around CHF 665 million and non-GAAP operating expenses around CHF 620 million (both measures include inventory build of around CHF 35 million and exclude unforeseen events)

Jean-Paul Clozel, MD and Chief Executive Officer, commented:

"The company is making great progress with delivering on the strategic priorities we defined on Day 1 of Idorsia. Now, just 4 years after establishing the company, we are on the verge of transformation into the fully-fledged biopharmaceutical company we intended to be. The regulatory review and the commercial preparation for daridorexant are progressing well and the team keeps its focus on this important asset. I'm also particularly proud of our newest advancement in the pipeline as selatogrel entered Phase 3 being evaluated as an emergency intervention for suspected AMI at the onset of symptoms. Yet another exciting innovation to watch for Idorsia."

Simon Jose, Chief Commercial Officer of Idorsia, commented:

"We are progressing very well with our preparations for the anticipated approval and launch of daridorexant. In the US, our new medical team is starting to engage with key experts and the recruitment of our market access team is nearing completion. In Europe, we have made great progress in building our commercial footprint and have appointed General Managers in the major markets. In the second half we will increase our engagement with key stakeholders and begin to raise awareness of the science and burden of insomnia. Similarly, we are on track with our plans for the expected launch of clazosentan in Japan - where the incidence of aSAH is more than twice as high as in the rest of the world."

Financial results

US GAAP results

First Half

Second Quarter

in CHF millions, except EPS (CHF) and number of shares (millions)

2021

2020

2021

2020

Revenues

14

58

7

53

Operating expenses

(265)

(236)

(137)

(120)

Operating income (loss)

(252)

(178)

(130)

(67)

Net income (loss)

(243)

(189)

(139)

(69)

Basic EPS

(1.46)

(1.41)

(0.83)

(0.51)

Basic weighted average number of shares

166.9

133.8

167.1

136.4

Diluted EPS

(1.46)

(1.41)

(0.83)

(0.51)

Diluted weighted average number of shares

166.9

133.8

167.1

136.4

US GAAP revenue of CHF 14 million in the first half of 2021 consisted of contract revenue recognized in connection with the collaboration agreements with Neurocrine Biosciences, Inc. (CHF 2 million), Janssen Biotech, Inc. (CHF 5 million), Roche (CHF 4 million), Mochida Pharmaceutical Co., Ltd (CHF 3 million) and revenue share from J&J (CHF 0.4 million) compared to a revenue of CHF 58 million in the first half of 2020.

US GAAP operating expenses in the first half of 2021 amounted to CHF 265 million (CHF 236 million in the first half of 2020), of which CHF 192 million relates to R&D (CHF 197 million in the first half of 2020) and CHF 74 million to SG&A expenses (CHF 40 million in the first half of 2020).

US GAAP net loss in the first half of 2021 amounted to CHF 243 million compared to CHF 189 million in the first half of 2020. The increase of the net loss was mainly driven by lower contract revenues as well as higher operating expenses mainly in the commercial functions, which was partially offset by a positive contribution from financial income.

The US GAAP net loss resulted in a net loss per share of CHF 1.46 (basic and diluted) in the first half of 2021 compared to a net loss per share of CHF 1.41 (basic and diluted) in the first half of 2020.

Idorsia announces financial results for the first half 2021 - Building momentum towards becoming a fully-fledged biopharmaceutical company ∙ Page 2 of 6

Non-GAAP* measures

First Half

Second Quarter

in CHF millions, except EPS (CHF) and number of shares (millions)

2021

2020

2021

2020

Revenues

14

58

7

53

Operating expenses

(248)

(193)

(128)

(86)

Operating income (loss)

(234)

(134)

(121)

(33)

Net income (loss)

(223)

(138)

(128)

(36)

Basic EPS

(1.34)

(1.03)

(0.77)

(0.26)

Basic weighted average number of shares

166.9

133.8

167.1

136.4

Diluted EPS

(1.34)

(1.03)

(0.77)

(0.26)

Diluted weighted average number of shares

166.9

133.8

167.1

136.4

  • Idorsia measures, reports and issues guidance on non-GAAP operating performance. Idorsia believes that these non-GAAP financial measurements more accurately reflect the underlying business performance and therefore provide useful supplementary information to investors. These non-GAAP measures are reported in addition to, not as a substitute for, US GAAP financial performance.

Non-GAAP net loss in the first half of 2021 amounted to CHF 223 million: the CHF 20 million difference versus US GAAP net loss was mainly due to depreciation and amortization (CHF 8 million), share-based compensation (CHF 8 million) and a negative non-cash financial result (CHF 4 million).

The non-GAAP net loss resulted in a net loss per share of CHF 1.34 (basic and diluted) in the first half of 2021 compared to a net loss per share of CHF 1.03 (basic and diluted) in the first half of 2020.

André C. Muller, Chief Financial Officer, commented:

"I'm pleased to now see a regular income stream, albeit modest, with the revenue-sharing agreement relating to ponesimod, which was launched by J&J in the second quarter following its approval for relapsing forms of multiple sclerosis in the US and EU. With regulatory discussions for daridorexant in the US and Europe, and clazosentan in Japan, progressing well, the investment into our global commercial infrastructure and launch preparations will gradually increase over the next quarters leading to US GAAP operating expenses for the full year 2021 around CHF 665 million and non-GAAP operating expenses around CHF 620 million, both measures include an inventory build of around CHF 35 million and exclude unforeseen events."

Liquidity and indebtedness

At the end of the first half of 2021, Idorsia's liquidity (including cash, cash equivalents, short- and long- term deposits) amounted to CHF 927 million.

(in CHF millions)

Jun 30, 2021

Mar 31, 2021

Dec 31, 2020

Liquidity

Cash and cash equivalents

164

128

141

Short-term deposits

763

741

867

Long-term deposits

-

196

192

Total liquidity*

927

1,065

1,200

Indebtedness

Convertible loan

392

390

388

Convertible bond

199

199

199

Other financial debt

-

-

-

Total indebtedness

592

589

587

*rounding differences may occur

Idorsia announces financial results for the first half 2021 - Building momentum towards becoming a fully-fledged biopharmaceutical company ∙ Page 3 of 6

Clinical Development

Idorsia has a diversified and balanced clinical development pipeline covering multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.

In April and July of 2020, Idorsia reported positive results in each of the two pivotal Phase 3 studies of daridorexant in patients with insomnia. More details and commentary can be found in the dedicated press releases (first study release), (second study release) and the investor webcasts (first study webcast), (second study webcast) which are available for replay on Idorsia's corporate website. A New Drug Application (NDA) for daridorexant was submitted to the US FDA on January 8, 2021 and a Marketing Authorization Application (MAA) to the European Union EMA on March 2, 2021 and to Switzerland health authority, Swissmedic, on April 20, 2021. Should approval be received, the company anticipates launch in the US in the second quarter of 2022, followed by other regions thereafter.

In November of 2020, Idorsia reported positive results in each of the two Japanese registration studies of clazosentan assessing the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause mortality in patients following aSAH. More details can be found in the dedicated press release. A New Drug Application (NDA) to the Japanese PMDA for clazosentan was submitted on March 1, 2021. Due to the intensive care setting for the study, recruitment into the global Phase 3 study of clazosentan (REACT) has been impacted by the coronavirus pandemic but is steadily progressing. The study is enrolling approximately 400 patients with a high risk of developing cerebral vasospasm and delayed cerebral ischemia (high-risk prevention group). The recruitment of patients with confirmed cerebral vasospasm (early treatment group) has been very low, so following a recommendation received by the study Independent Data Monitoring Committee (IDMC), the company has decided to discontinue this relatively small treatment group. Results continue to be expected in the second half of 2022.

The MODIFY Phase 3 study of Idorsia's oral substrate reduction therapy lucerastat in patients with Fabry disease irrespective of mutation type was fully recruited in February 2021, with 118 patients. Results continue to be expected in the fourth quarter of this year.

Full recruitment has also been achieved for PRECISION, a Phase 3 study to demonstrate the antihypertensive effect of aprocitentan when added to standard of care in patients with resistant hypertension, with 730 patients randomized. This 12-month study should deliver results in mid-2022.

In June 2021, Idorsia announced the initiation of a Phase 3 registration study "SOS-AMI" to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia's P2Y12 receptor antagonist, in suspected acute myocardial infarction (AMI). More details and commentary can be found in the dedicated press releaseand the investor webcast.

The CARE study, a large Phase 2b multiple-dose, efficacy and safety study evaluating cenerimod, for the treatment of systemic lupus erythematosus completed randomization at the end of February 2021, with 427 patients enrolled. The results are targeted for the fourth quarter of 2021.

A Phase 2 proof-of-concept study with ACT-539313, a selective orexin 1 receptor antagonist, in binge eating disorder is recruiting. This is the first study evaluating orexin 1 receptor antagonism as a new mechanism of action for patients with binge eating disorder.

Based on initial clinical pharmacology investigation with ACT-541478, the company has decided not to pursue the development of this CNS compound further.

Idorsia announces financial results for the first half 2021 - Building momentum towards becoming a fully-fledged biopharmaceutical company ∙ Page 4 of 6

The company has closed a natural history study called "RETRIEVE" which collected disease information from pediatric patients with early onset of rare lysosomal storage disorders (LSDs). The company is now considering development options for sinbaglustat.

Neurocrine Biosciences recently initiated a second Phase 2 study with ACT-709478(NBI-827104), Idorsia's novel T-type calcium channel blocker, in patients with essential tremor, in addition to the ongoing Phase 2 study in a rare form of pediatric epilepsy.

Idorsia's clinical development pipeline

Compound

Mechanism of Action

Target Indication

Status

Daridorexant

Dual orexin receptor

Insomnia

Under review with

antagonist

health authorities

Aprocitentan*

Dual endothelin receptor

Resistant hypertension

Phase 3 recruitment

antagonist

management

complete

Endothelin receptor

Cerebral vasospasm assoc.

Japan: NDA submitted

Clazosentan

with aneurysmal subarachnoid

antagonist

hemorrhage

Global: Phase 3

Lucerastat

Glucosylceramide synthase

Fabry disease

Phase 3 recruitment

inhibitor

complete

Selatogrel

P2Y12 receptor antagonist

Suspected acute myocardial

Phase 3

infarction

Cenerimod

S1P1 receptor modulator

Systemic lupus erythematosus

Phase 2b recruitment

complete

ACT-539313

Selective orexin 1 receptor

Binge eating disorder

Phase 2

antagonist

Sinbaglustat

GBA2/GCS inhibitor

Rare lysosomal storage

Phase 1 complete

disorders

ACT-1004-1239

CXCR7 antagonist

Immunology

Phase 1

ACT-1014-6470

-

Immunology

Phase 1

ACT-777991

-

Immunology

Phase 1

* In collaboration with Janssen Biotech to jointly develop aprocitentan, Janssen Biotech has sole commercialization rights worldwide

Neurocrine Biosciences has a global license to develop and commercialize ACT-709478(NBI-827104), Idorsia's novel T-type calcium channel blocker. ACT-709478 is currently investigated in two Phase 2 studies for the treatment of a rare form of pediatric epilepsy and essential tremor.

Further details including the current status of each project in the pipeline can be found in our clinical development fact sheet.

Idorsia announces financial results for the first half 2021 - Building momentum towards becoming a fully-fledged biopharmaceutical company ∙ Page 5 of 6

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Idorsia Ltd. published this content on 27 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 July 2021 05:19:02 UTC.